Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for BIIB122/DNL151 (LRRK2 Inhibitor) in Parkinson's disease. The expected timing is based on the latest available company guidance and may change.
LUMA/LIGHTHOUSE trials. Collab w/ Biogen. 05/2022- Initiated trial. 01/24- collab agreement initiated w/ a third party for a global Ph2a study, starting in 2024. Biogen to continue the trial and co-commercialize w/ DNLI. 5/6/25- Ph2b data expected in 2026. 11/06/25:- Ph2b LUMA study completed enrollment earlier in 2025, and a data readout remains expected in 2026 while the Ph2a BEACON study continues. 02/26/26:- Global Ph2b LUMA study readout for early Parkinson's expected in Mid-2026; Biogen collaboration continues. 05/07/26:- Global Ph2b LUMA data readout for early Parkinson's still expected in Mid-2026; BEACON Ph2a study ongoing. 08/06/26:- LUMA missed endpoints; DNL151 discontinued in idiopathic Parkinson's disease.
Verification
Confirm timing and program details against the company announcement or filing.